Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...